Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Global Burden of Viral Hepatitis From 1990 to 2013: Findings From the Global Burden of Disease Study 2013 Publisher Pubmed



Stanaway JD1 ; Flaxman AD1 ; Naghavi M1 ; Fitzmaurice C1, 2 ; Vos T1 ; Abubakar I3 ; Aburaddad LJ4 ; Assadi R5 ; Bhala N6, 7 ; Cowie B8, 9 ; Forouzanfour MH1 ; Groeger J10 ; Hanafiah KM11, 12 ; Jacobsen KH13 Show All Authors
Authors
  1. Stanaway JD1
  2. Flaxman AD1
  3. Naghavi M1
  4. Fitzmaurice C1, 2
  5. Vos T1
  6. Abubakar I3
  7. Aburaddad LJ4
  8. Assadi R5
  9. Bhala N6, 7
  10. Cowie B8, 9
  11. Forouzanfour MH1
  12. Groeger J10
  13. Hanafiah KM11, 12
  14. Jacobsen KH13
  15. James SL14
  16. Maclachlan J8, 9
  17. Malekzadeh R15
  18. Martin NK16, 17
  19. Mokdad AA18
  20. Mokdad AH1
  21. Murray CJL1
  22. Plass D19
  23. Rana S20, 21
  24. Rein DB22
  25. Richardus JH23
  26. Sanabria J24, 25
  27. Saylan M26
  28. Shahraz S27
  29. So S28
  30. Vlassov VV29
  31. Weiderpass E30, 31, 32, 33
  32. Wiersma ST34
  33. Younis M35
  34. Yu C36
  35. El Sayed Zaki M37
  36. Cooke GS38

Source: The Lancet Published:2016


Abstract

Background With recent improvements in vaccines and treatments against viral hepatitis, an improved understanding of the burden of viral hepatitis is needed to inform global intervention strategies. We used data from the Global Burden of Disease (GBD) Study to estimate morbidity and mortality for acute viral hepatitis, and for cirrhosis and liver cancer caused by viral hepatitis, by age, sex, and country from 1990 to 2013. Methods We estimated mortality using natural history models for acute hepatitis infections and GBD's cause-of-death ensemble model for cirrhosis and liver cancer. We used meta-regression to estimate total cirrhosis and total liver cancer prevalence, as well as the proportion of cirrhosis and liver cancer attributable to each cause. We then estimated cause-specific prevalence as the product of the total prevalence and the proportion attributable to a specific cause. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs). Findings Between 1990 and 2013, global viral hepatitis deaths increased from 0·89 million (95% uncertainty interval [UI] 0·86–0·94) to 1·45 million (1·38–1·54); YLLs from 31·0 million (29·6–32·6) to 41·6 million (39·1–44·7); YLDs from 0·65 million (0·45–0·89) to 0·87 million (0·61–1·18); and DALYs from 31·7 million (30·2–33·3) to 42·5 million (39·9–45·6). In 2013, viral hepatitis was the seventh (95% UI seventh to eighth) leading cause of death worldwide, compared with tenth (tenth to 12th) in 1990. Interpretation Viral hepatitis is a leading cause of death and disability worldwide. Unlike most communicable diseases, the absolute burden and relative rank of viral hepatitis increased between 1990 and 2013. The enormous health loss attributable to viral hepatitis, and the availability of effective vaccines and treatments, suggests an important opportunity to improve public health. Funding Bill & Melinda Gates Foundation. © 2016 Elsevier Ltd
Other Related Docs